State Ledger
Company profile

CG Oncology, Inc. CIK 1991792

Ticker
CGON (Nasdaq)
Industry
Biological Products, (No Diagnostic Substances)
Headquarters
Dallas, TX 75247
Fiscal year end
2025 (FY)
Market Data
Close
$63.14
Change
-$0.69
Change %
-1.08%
Volume
17,742

CGON · trading date Oct 12, 2026 · previous close $63.83 · source: Alpaca (IEX feed, not consolidated full-market data).

Key Financials
Revenue
—
Net income
-$161.00M
Total assets
$791.59M
Total liabilities
$38.99M
Stockholders' equity
$752.60M
Cash & equivalents
$32.49M
Operating income
-$190.77M
Operating cash flow
-$132.35M
Capital expenditures
$134.0K

Fiscal year 2025, via 10-K filed 2026-02-27. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.

Financial Performance
Operating margin
—
Net margin
—
Free cash flow
-$132.48M
Free cash flow margin
—
Liabilities / assets
4.9%
Equity / assets
95.1%
CapEx / revenue
—
Operating cash flow / net income
0.82×

Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.

Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025 — -$161.00M $791.59M $38.99M $752.60M
2024 — -$88.04M $754.80M $21.42M $733.38M
2023 — -$48.61M $199.30M $14.51M -$123.10M
Company Details
SIC code
2836
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 144
2026-09-17
Financials filed via
Form 10-K
filed 2026-02-27

"Most recent SEC filing" may differ from the filing used for the financial figures above.

Location
Dallas, TX 75247
3000 PEGASUS PARK DRIVE
Data & Methodology

SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:58 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.

← Back to Texas — Public Companies